These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

384 related articles for article (PubMed ID: 33141071)

  • 1. A novel dopamine D3R agonist SK609 with norepinephrine transporter inhibition promotes improvement in cognitive task performance in rodent and non-human primate models of Parkinson's disease.
    Schneider JS; Marshall CA; Keibel L; Snyder NW; Hill MP; Brotchie JM; Johnston TH; Waterhouse BD; Kortagere S
    Exp Neurol; 2021 Jan; 335():113514. PubMed ID: 33141071
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Selective activation of Dopamine D3 receptors and norepinephrine transporter blockade enhances sustained attention.
    Marshall CA; Brodnik ZD; Mortensen OV; Reith MEA; Shumsky JS; Waterhouse BD; España RA; Kortagere S
    Neuropharmacology; 2019 Apr; 148():178-188. PubMed ID: 30633928
    [TBL] [Abstract][Full Text] [Related]  

  • 3. In vivo characterization of a novel dopamine D3 receptor agonist to treat motor symptoms of Parkinson's disease.
    Simms SL; Huettner DP; Kortagere S
    Neuropharmacology; 2016 Jan; 100():106-15. PubMed ID: 25896768
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Functional Characterization of a Novel Series of Biased Signaling Dopamine D3 Receptor Agonists.
    Xu W; Wang X; Tocker AM; Huang P; Reith ME; Liu-Chen LY; Smith AB; Kortagere S
    ACS Chem Neurosci; 2017 Mar; 8(3):486-500. PubMed ID: 27801563
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Limitations of the rat medial forebrain lesion model to study prefrontal cortex mediated cognitive tasks in Parkinson's disease.
    Marshall CA; King KM; Kortagere S
    Brain Res; 2019 Jan; 1702():105-113. PubMed ID: 29608880
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Intranasal and subcutaneous administration of dopamine D3 receptor agonists functionally restores nigrostriatal dopamine in MPTP-treated mice.
    Lao CL; Kuo YH; Hsieh YT; Chen JC
    Neurotox Res; 2013 Nov; 24(4):523-31. PubMed ID: 23820985
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Implication of dopamine D3 receptor activation in the reversion of Parkinson's disease-related motivational deficits.
    Carnicella S; Drui G; Boulet S; Carcenac C; Favier M; Duran T; Savasta M
    Transl Psychiatry; 2014 Jun; 4(6):e401. PubMed ID: 24937095
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Motor response to a dopamine D3 receptor preferring agonist compared to apomorphine in levodopa-primed 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine monkeys.
    Blanchet PJ; Konitsiotis S; Chase TN
    J Pharmacol Exp Ther; 1997 Nov; 283(2):794-9. PubMed ID: 9353400
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Dopamine transporter loss in 6-OHDA Parkinson's model is unmet by parallel reduction in dopamine uptake.
    Chotibut T; Apple DM; Jefferis R; Salvatore MF
    PLoS One; 2012; 7(12):e52322. PubMed ID: 23300642
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effects of noradrenergic denervation by anti-DBH-saporin on behavioral responsivity to L-DOPA in the hemi-parkinsonian rat.
    Ostock CY; Lindenbach D; Goldenberg AA; Kampton E; Bishop C
    Behav Brain Res; 2014 Aug; 270():75-85. PubMed ID: 24837745
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Novel D3 dopamine receptor-preferring agonist D-264: Evidence of neuroprotective property in Parkinson's disease animal models induced by 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine and lactacystin.
    Li C; Biswas S; Li X; Dutta AK; Le W
    J Neurosci Res; 2010 Aug; 88(11):2513-23. PubMed ID: 20623619
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Chronic alterations in dopaminergic neurotransmission produce a persistent elevation of deltaFosB-like protein(s) in both the rodent and primate striatum.
    Doucet JP; Nakabeppu Y; Bedard PJ; Hope BT; Nestler EJ; Jasmin BJ; Chen JS; Iadarola MJ; St-Jean M; Wigle N; Blanchet P; Grondin R; Robertson GS
    Eur J Neurosci; 1996 Feb; 8(2):365-81. PubMed ID: 8714707
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Dopamine D1 receptor agonism induces dynamin related protein-1 inhibition to improve mitochondrial biogenesis and dopaminergic neurogenesis in rat model of Parkinson's disease.
    Mishra A; Singh S; Tiwari V; Bano S; Shukla S
    Behav Brain Res; 2020 Jan; 378():112304. PubMed ID: 31626851
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Antidyskinetic effect of A2A and 5HT1A/1B receptor ligands in two animal models of Parkinson's disease.
    Pinna A; Ko WK; Costa G; Tronci E; Fidalgo C; Simola N; Li Q; Tabrizi MA; Bezard E; Carta M; Morelli M
    Mov Disord; 2016 Apr; 31(4):501-11. PubMed ID: 26871939
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Current concepts in treating mild cognitive impairment in Parkinson's disease.
    Schneider JS; Kortagere S
    Neuropharmacology; 2022 Feb; 203():108880. PubMed ID: 34774549
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Synergistic antidyskinetic effects of topiramate and amantadine in animal models of Parkinson's disease.
    Kobylecki C; Hill MP; Crossman AR; Ravenscroft P
    Mov Disord; 2011 Nov; 26(13):2354-63. PubMed ID: 21953539
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Associative and limbic regions of monkey striatum express high levels of dopamine D3 receptors: effects of MPTP and dopamine agonist replacement therapies.
    Morissette M; Goulet M; Grondin R; Blanchet P; Bédard PJ; Di Paolo T; Lévesque D
    Eur J Neurosci; 1998 Aug; 10(8):2565-73. PubMed ID: 9767387
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Sumanirole, a highly dopamine D2-selective receptor agonist: in vitro and in vivo pharmacological characterization and efficacy in animal models of Parkinson's disease.
    McCall RB; Lookingland KJ; Bédard PJ; Huff RM
    J Pharmacol Exp Ther; 2005 Sep; 314(3):1248-56. PubMed ID: 15980060
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Paradoxical effect of dopamine medication on cognition in Parkinson's disease: relationship to side of motor onset.
    Hanna-Pladdy B; Pahwa R; Lyons KE
    J Int Neuropsychol Soc; 2015 Apr; 21(4):259-70. PubMed ID: 25923830
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The intranasal administration of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP): a new rodent model to test palliative and neuroprotective agents for Parkinson's disease.
    Prediger RD; Aguiar AS; Moreira EL; Matheus FC; Castro AA; Walz R; De Bem AF; Latini A; Tasca CI; Farina M; Raisman-Vozari R
    Curr Pharm Des; 2011; 17(5):489-507. PubMed ID: 21375482
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.